Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance
Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.
You may also be interested in...
US FDA's EUA allows lower doses of the two antibodies than were tested in BLAZE-1, which should extend current supply. With Amgen, Lilly hopes to manufacture 1 million doses by mid-year.
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.